XBiotech Inc.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
XBIT$1.97+3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Net loss | $(38,531) | $(24,557) |
| Foreign currency translation adjustment | - | (252) |
| Reclassification of deferred tax assets | - | (574) |
| Comprehensive loss | $(38,531) | $(25,383) |
See accompanying notes to consolidated financial statements.
Consolidated Statements of Shareholders' Equity
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.